AU2024301186A1 — Novel composition for suspension formulation
Assigned to Axxelent Pharma Science Private Ltd · Expires 2026-02-05 · 0y expired
What this patent protects
The present invention concerns a pharmaceutical composition, advantageously a ready-to-use liquid composition or dry powder for reconstitution, comprising: Cenobamate or a salt, hydrate or solvate thereof, wherein the pharmaceutical composition for administration is preferably a …
USPTO Abstract
The present invention concerns a pharmaceutical composition, advantageously a ready-to-use liquid composition or dry powder for reconstitution, comprising: Cenobamate or a salt, hydrate or solvate thereof, wherein the pharmaceutical composition for administration is preferably a suspension for oral administration, a kit of parts for the accurate dosing and administration of the pharmaceutical composition. Further the present composition having at least one surface modifying agent controlling the solid state of Cenobamate in suspension; and a method for the treatment of partial seizures in a human patient comprising administration of a therapeutically effective amount of the pharmaceutical composition.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.